ProfileGDS5678 / 1424985_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 80% 80% 78% 80% 82% 84% 82% 80% 80% 80% 80% 80% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6332280
GSM967853U87-EV human glioblastoma xenograft - Control 25.7191980
GSM967854U87-EV human glioblastoma xenograft - Control 35.641580
GSM967855U87-EV human glioblastoma xenograft - Control 45.5862378
GSM967856U87-EV human glioblastoma xenograft - Control 55.6818580
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7351682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0548284
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8770482
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.697180
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7127880
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7063680
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7053980
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.71180
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.711881